PCSA (Processa Pharmaceuticals) Other Operating Expense: $0.00 Mil (TTM As of Mar. 2026)


PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $2.16
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Other Operating Expense?

Processa Pharmaceuticals PCSA +9.64% 28 Other Operating Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Processa Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Processa Pharmaceuticals's annual Other Operating Expense increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Processa Pharmaceuticals Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Other Operating Expense Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Processa Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.00 Mil mean?
Processa Pharmaceuticals (PCSA) has a Other Operating Expense of $0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Processa Pharmaceuticals and its competitors.
Is Processa Pharmaceuticals' Other Operating Expense too high?
Processa Pharmaceuticals' current Other Operating Expense is $0.00 Mil. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Other Operating Expense compare to ELAB and MBIO?
Processa Pharmaceuticals' Other Operating Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Other Operating Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Other Operating Expense of $0.00 Mil. The current Other Operating Expense is $0.00 Mil. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Other Operating Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price